CAJ | 학술논문

依维莫司（everolimus）是雷帕霉素的40-O-2-(羟乙基)衍生物，为哺乳动物雷帕霉素靶蛋白（mTOR）抑制剂。除了免疫抑制作用外，它能持续抑制mTOR靶点，达到抑制肿瘤生长与增殖、抑制肿瘤营养代谢和抑制肿瘤新生血管形成等三重抗肿瘤作用。在国外已被批准用于治疗晚期肾癌、乳腺癌、不能外科切除的进展性或转移性胰腺神经内分泌瘤以及伴有结节性硬化症（TSC）的室管膜下巨细胞星形细胞瘤（SEGA）；在我国也已被批准用于晚期肾癌。依维莫司对其他的肿瘤的疗效及安全性也正在进行临床试验。本文简要介绍依维莫司的作用机制以及在肿瘤治疗中的临床应用。
의유막사（everolimus）시뢰파매소적40-O-2-(간을기)연생물，위포유동물뢰파매소파단백（mTOR）억제제。제료면역억제작용외，타능지속억제mTOR파점，체도억제종류생장여증식、억제종류영양대사화억제종류신생혈관형성등삼중항종류작용。재국외이피비준용우치료만기신암、유선암、불능외과절제적진전성혹전이성이선신경내분비류이급반유결절성경화증（TSC）적실관막하거세포성형세포류（SEGA）；재아국야이피비준용우만기신암。의유막사대기타적종류적료효급안전성야정재진행림상시험。본문간요개소의유막사적작용궤제이급재종류치료중적림상응용。
Everolimus, a 40-O-[2-hydroxyethyl]derivative of rapamycin, is a mammalian target of rapamycin inhibitor. Excepting immunosuppression, everolimus exhibits an ability of continuously inhibiting mammalian target of rapamycin(mTOR), which may contribute to its triple activity of inhibiting development and proliferation, nutrition metabolism and angiogenesis of tumors. Everolimus has been approved overseas for the treatment of advanced metastatic renal cell carcinoma, breast cancer, ad-vanced pancreatic neuroendocrine tumor and subependymal giant-cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC). In China, everolimus has just been approved for treating advanced metastatic renal cell carcinoma so far. The safety and efficacy of everolimus is still being studied on other tumors. In this review, it is focused to briefly introduce the mecha-nism and anti-cancer efficacy of everolimus.